Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Challenging the Role of Maintenance Therapy in FL

January 5th 2018

Upfront Therapy Strategies in Follicular Lymphoma

January 5th 2018

Follicular Lymphoma: Outcomes After Immunochemotherapy

January 5th 2018

Biomarker Testing Continues to Develop in NSCLC

December 28th 2017

Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.

Molecular Testing Advancements Leading Field of GI Cancers

December 26th 2017

Shirley Michelle Shiller, DO, discusses progress with precision medicine for patients with gastrointestinal cancers.

Gastric/GEJ Cancers: Looking Toward the Future

December 22nd 2017

The Evolving Treatment Landscape in Gastric/GEJ Cancers

December 22nd 2017

Gastric/GEJ Cancers: Non-Immunotherapeutic Advancements

December 22nd 2017

Other Immunotherapy Approaches in Gastric/GEJ Cancers

December 22nd 2017

Emerging Nivolumab Strategies in Gastric/GEJ Cancers

December 22nd 2017

Practical Considerations for Prescribing Immunotherapy

December 22nd 2017

MSI Testing's Impact on Immunotherapy in Gastric Cancers

December 22nd 2017

Immunotherapy in Advanced/Metastatic Gastric/GEJ Cancers

December 22nd 2017

Advanced/Metastatic Gastric Cancer: Beyond Frontline

December 22nd 2017

Treating Unresectable or Metastatic Gastric/GEJ Cancers

December 22nd 2017

Upfront Therapy Approaches in Gastric/GEJ Cancer

December 22nd 2017

Understanding Prognoses of Advanced Gastric/GEJ cancers

December 22nd 2017

The Molecular-Driven Classification of Gastric Cancers

December 22nd 2017

Classification Guidelines for Gastric/GEJ Cancers

December 22nd 2017

Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer

December 14th 2017

The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,